oral semaglutide for obesity Wegovy approved management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Transformative arrival of oral weight

You now have portioned servings ready for the entire week

The above information should not be used to diagnose, treat, or prevent any disease or medical condition

Indicators of kidney damage include: Less frequent urination Fatigue Shortness of breath Nausea Chest Pain Kidney damage can have serious long-term effects on a person

If the needle is too short: The medication may be delivered intradermally (into the skin layers)

Most recent policy updates reviewed: December 2025 Government Programs: What's Changing Medicare Coverage Expanding Medicare coverage for Wegovy is expanding for eligible beneficiaries: January 2027: Under the CMS BALANCE Model, Medicare Part D will cover obesity medications including Wegovy CMS program: Eligible Medicare beneficiaries will pay $50/month for GLP-1 medications under the BALANCE demonstration Current: Wegovy can be covered for CV risk reduction indication (not weight loss) Medicaid Coverage: State-by-State About a dozen state Medicaid programs currently cover GLP-1s for obesity, with policies evolving

Using it purely for cosmetic weight loss without a BMI or metabolic health indication is not what the drug was designed for